What is C2N Diagnostics?
C2N Diagnostics operates with a vision to bring Clarity Through Innovation in the field of brain health. The company provides specialized laboratory services and products crucial for clinical decision-making, aiming to improve patient diagnosis and treatment monitoring. Furthermore, C2N's offerings are instrumental in enhancing the quality and efficiency of clinical trials for novel neurodegeneration treatments. They also supply innovative tools to healthcare researchers, facilitating a deeper understanding of disease mechanisms, identification of new therapeutic targets, and the execution of vital epidemiologic studies to bolster global public health initiatives.
How much funding has C2N Diagnostics raised?
C2N Diagnostics has raised a total of $40M across 3 funding rounds:
Grant
$15M
Unspecified
$15M
Other Financing Round
$10M
Grant (2023): $15M with participation from GHR Foundation
Unspecified (2024): $15M led by us.eisai.com
Other Financing Round (2025): $10M supported by Samsung C&T
Key Investors in C2N Diagnostics
Samsung C&T
Samsung C&T, a diversified South Korean conglomerate with roots dating back to 1938, operates across various sectors including resorts, fashion, trade, and engineering. Their investment in C2N Diagnostics suggests a strategic interest in the burgeoning field of advanced diagnostics and healthcare innovation.
us.eisai.com
Eisai Co., Ltd., a global pharmaceutical company, is driven by its 'hhc' (human health care) philosophy, emphasizing patient needs as the core of its business. Their participation indicates a focus on neurodegenerative diseases and therapeutic development, aligning with C2N Diagnostics' mission.
GHR Foundation
GHR Foundation is a philanthropic organization dedicated to transformative work, particularly in Alzheimer's prevention and global health. Their backing of C2N Diagnostics highlights a commitment to advancing solutions for neurodegenerative diseases and improving patient outcomes.
What's next for C2N Diagnostics?
The substantial enterprise-level funding and recent strategic investment position C2N Diagnostics for accelerated growth and expanded research capabilities. This infusion of capital is expected to fuel the company's innovation pipeline, enabling further development of its biomarker services and products. C2N Diagnostics is poised to solidify its market leadership in brain health diagnostics, driving advancements in patient care and therapeutic development for neurodegenerative conditions.
See full C2N Diagnostics company page
